Q-omics provides the consensus-scored TXNL4B profile across patient tissues and cancer cell-line models. TXNL4B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TXNL4B is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TXNL4B protein abundance shows 20,454 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight ACC, HNSC, and CCRCC as cancer lineages where TXNL4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TXNL4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TXNL4B survival associations across molecular data types. TXNL4B RNA expression shows survival associations in the most cancer types (26), followed by mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TXNL4B RNA expression–survival associations across cancer types. High TXNL4B expression shows unfavorable associations in ACC, LGG, LIHC and KIRC, but favorable associations in MESO and THYM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TXNL4B RNA expression.
This table summarizes TXNL4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 13. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TXNL4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TXNL4B shows higher tumor expression in HNSC, KIRC, BLCA, LIHC, KIRP and COAD. The HNSC box plot shows higher TXNL4B RNA expression in tumor versus normal tissue (log2 FC = +0.850, t-test p < 0.001).
This table shows molecular features associated with TXNL4B in patient tissues and cancer cell lines. In patient samples, TXNL4B shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TXNL4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
